Kawasaki disease in siblings and a review of drug treatment

Article Details

Steven King-fan Loo MBChB, FRCP, Kam Lun Hon MBBS, MD, FAAP, FCCM, Alexander KC Leung MBBS, FRCPC, FRCP (UK & Irel), FRCPCH, FAAP, Tak Cheung Yung MBBS, MRCPCH, Man Ching Yam MBChB, MRCPCH

Article Type
Case Report


Related Articles

Article Page


We have managed two anonymized siblings with Kawasaki disease (KD). The occurrence of KD in the elder brother alerted us to the occurrence of incomplete KD in the younger brother. Both siblings were treated with intravenous immunoglobulin and a high dose of dipyridamole with resolution of the coronary artery aneurysm. Dipyridamole was used instead of aspirin because both siblings were glucose-6-phosphate dehydrogenase deficient for which aspirin was contraindicated. To prevent damage to the coronary arteries, treatment should be started as soon as the diagnosis is made. There have been a lot of advances in medical therapy in recent years, which are reviewed together with conventional proven therapy for KD. Early diagnosis and prompt treatment are important to achieve optimal treatment outcome in KD. Family history of KD among siblings enables clinicians for an earlier diagnosis so as to prevent the disease complications particularly in patients with incomplete features.

Keywords: COVID-19, dipyridamole, intravenous immunoglobulin, Kawasaki disease, siblings.

Citation: Loo SK, Hon KL, Leung AKC, Yung TC, Yam MC. Kawasaki disease in siblings and a review of drug treatment. Drugs in Context 2020; 9: 2020-4-1. DOI: 10.7573/dic.2020-4-1

Contributions: All authors contributed equally to the preparation of this review. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/06/dic.2020-4-1-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2020 Loo SK, Hon KL, Leung AKC, Yung TC, Yam MC. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

Correct attribution: Copyright © 2020 Loo SK, Hon KL, Leung AKC, Yung TC, Yam MC. https://doi.org/10.7573/dic.2020-4-1. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://www.drugsincontext.com/kawasaki-disease-in-siblings-and-a-review-of-drug-treatment

Correspondence: Kam Lun Ellis Hon, Department of Paediatrics, The Chinese University of Hong Kong, 6/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, Hong Kong. ehon@hotmail.com

Provenance: invited; externally peer reviewed.

Submitted: 2 April 2020; Peer review comments to author: 18 May 2020; Revised manuscript received: 5 June 2020; Accepted: 8 June 2020; Publication date: 7 July 2020.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editorial office editorial@drugsincontext.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF